venoplant gdue biotrap argivit duonorm aurastop venoplant gdue biotrap argivit duonorm aurastop venoplant gdue biotrap argivit duonorm aurastop

Ursolisin

Ursodeoxycholic acid

Ursolisin

Active substance

Ursodeoxycholic acid

Strenght and pharmaceutical forms

​150 mg hard capsules – 20 hard capsules
150 mg hard capsules – 30 hard capsules
150 mg hard capsules – 40 hard capsules
300 mg hard capsules – 10 hard capsules
300 mg hard capsules – 20 hard capsules

ATC

A05AA02 - Hepatobiliary antilithogen, litolithic

Therapeutic Indications

Qualitative and quantitative alterations of biligenetic function, including bile-overexpressing cholesterol forms, to oppose the formation of cholesterol calculations or to achieve conditions for dissolution if radiolucent calculations already exist: in particular, gallbladder stones in functional gallbladder and calculations in residual choledocus or recurrent ones after surgery on the bile ducts; Biliary dyspepsia.

Marketing Authorization Holder

Magis Farmaceutici S.r.l.

Download area

Summary of Product Characteristics - Ursolisin

Clinical Review from British Journal of Medicine & Medical Research


Products of the same therapeutic areas

Events

06-07/05/2023

 SIMPOSIO: ENDOCRINOLOGO, DIABETE, DISGLICEMIA E NUTRACEUTICI: NON PIU' ESPLORATORE IN TERRA INCOGNITA 

 Download

06-07/12/2019

XVI CONGR NAZ FLEBOFORUM- XIV SIMPOSIO MALATTIA VARICOSA- VII FLEB WINTER FARM

NAPOLI

XVI CONGR NAZ FLEBOFORUM- XIV SIMPOSIO MALATTIA VARICOSA- VII FLEB WINTER FARM

 Download